About Advaxis (NASDAQ:ADXS)
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Industry, Sector and Symbol
Trailing P/E Ratio-0.818565400843882
Forward P/E Ratio-1.12
Sales & Book Value
Annual Sales$12.03 million
Price / Sales8.44
Price / CashN/A
Book Value$1.32 per share
Price / Book1.47
Return on Equity-149.14%
Return on Assets-92.30%
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Monday, March, 12th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. View Advaxis' Earnings History.
When will Advaxis make its next earnings announcement?
Where is Advaxis' stock going? Where will Advaxis' stock price be in 2018?
2 equities research analysts have issued 12-month target prices for Advaxis' shares. Their predictions range from $5.00 to $6.00. On average, they anticipate Advaxis' stock price to reach $5.50 in the next year. View Analyst Ratings for Advaxis.
Are investors shorting Advaxis?
Advaxis saw a decrease in short interest in the month of February. As of February 28th, there was short interest totalling 5,217,154 shares, a decrease of 36.7% from the February 15th total of 8,237,640 shares. Based on an average daily trading volume, of 1,861,014 shares, the short-interest ratio is currently 2.8 days. Approximately 16.1% of the shares of the company are sold short.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Recro Pharma (REPH), Ovid Therapeutics (OVID), Synlogic (SYBX), Spero Therapeutics (SPRO), Ra Pharmaceuticals (RARX), Verona Pharma plc - American Depositary Share (VRNA), Nabriva Therapeutics (NBRV), Kamada (KMDA), Nymox Pharmaceutical (NYMX), Foamix Pharmaceuticals (FOMX), Zafgen (ZFGN), Spring Bank Pharmaceuticals (SBPH), ArQule (ARQL), Newron Pharma (NWPHF), XOMA (XOMA), Summit Therapeutics (SMMT), Aratana Therapeutics (PETX) and vTv Therapeutics (VTVT).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- David Sidransky M.D., Independent chairman of the Board (Age 57)
- Anthony Lombardo, Interim Chief Executive Officer (Age 70)
- Sara M. Bonstein, Chief Financial Officer, Executive Vice President (Age 37)
- Robert G. Petit Ph.D., Executive Vice President, Chief Scientific Officer (Age 58)
- James P. Patton M.D., Independent Non-Executive Vice Chairman of the Board (Age 60)
- Roni A. Appel, Independent Director (Age 51)
- Richard J. Berman J.D., Independent Director (Age 75)
- Samir N. Khleif, Independent Director (Age 54)
Has Advaxis been receiving favorable news coverage?
News headlines about ADXS stock have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advaxis earned a news sentiment score of 0.20 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.25 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Advaxis' major shareholders?
Advaxis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.49%), Renaissance Technologies LLC (1.19%), Deutsche Bank AG (1.12%), Bank of Montreal Can (1.05%), Bank of New York Mellon Corp (0.34%) and Franklin Street Advisors Inc. NC (0.31%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.
Which major investors are selling Advaxis stock?
ADXS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and BlackRock Inc.. Company insiders that have sold Advaxis company stock in the last year include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit and Sara Bonstein. View Insider Buying and Selling for Advaxis.
Which major investors are buying Advaxis stock?
ADXS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, Bank of Montreal Can, Franklin Street Advisors Inc. NC, Capital Analysts LLC, Cutler Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Advaxis.
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $1.94.
How big of a company is Advaxis?
Advaxis has a market capitalization of $107.24 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis. Advaxis employs 108 workers across the globe.
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (ADXS)MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Advaxis (NASDAQ:ADXS) Earnings History and Estimates Chart
Advaxis (NASDAQ ADXS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/12/2018||Q1 2018||($0.55)||($0.49)||$3.03 million||$2.06 million||View||Listen|
|12/20/2017||Q4 2017||($0.55)||($0.57)||$3.05 million||$1.76 million||View||Listen|
|9/11/2017||Q3||($0.53)||($0.80)||$3.43 million||$3.05 million||View||N/A|
|6/6/2017||Q2 2017||($0.49)||($0.51)||$3.79 million||$3.43 million||View||N/A|
|3/10/2017||Q1 2017||($0.52)||($0.43)||$2.15 million||$3.79 million||View||N/A|
|1/9/2017||Q4 2016||($0.55)||$3.75 million||View||N/A|
|6/8/2016||Q2 2016||($0.54)||($0.45)||$0.13 million||View||N/A|
|2/26/2016||Q1 2016||($0.41)||($0.59)||$0.10 million||$0.25 million||View||N/A|
|6/9/2014||Q3 2014||($0.25)||($0.30)||$1.00 million||View||N/A|
Advaxis (NASDAQ:ADXS) Earnings Estimates
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.72%
Institutional Ownership Percentage: 29.13%
Advaxis (NASDAQ ADXS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/2/2018||Anthony A Lombardo||CEO||Sell||32||$2.93||$93.76||92,903|| |
|1/3/2018||Sara Bonstein||CFO||Sell||5,224||$3.18||$16,612.32||229,237|| |
|11/6/2017||Robert Petit||Insider||Sell||3,723||$3.30||$12,285.90||220,917|| |
|11/6/2017||Sara Bonstein||CFO||Sell||3,862||$3.30||$12,744.60||227,908|| |
|11/2/2017||Anthony A Lombardo||CEO||Sell||24||$3.19||$76.56||92,935|| |
|11/2/2017||Robert Petit||Insider||Sell||12,625||$3.19||$40,273.75||237,265|| |
|11/2/2017||Sara Bonstein||CFO||Sell||12,734||$3.19||$40,621.46||244,504|| |
|10/11/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||600,000||$4.30||$2,580,000.00|| |
|9/26/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||1,239,323||$4.42||$5,477,807.66|| |
|3/31/2017||Robert Petit||Insider||Sell||2,454||$8.24||$20,220.96||122,051|| |
|12/30/2016||Sara Bonstein||CFO||Sell||5,520||$7.37||$40,682.40||131,963|| |
|12/20/2016||Thomas J Mckearn||Director||Sell||12,316||$8.08||$99,513.28||69,804|| |
|11/2/2016||Daniel O'connor||CEO||Sell||8,240||$8.32||$68,556.80||303,127|| |
|11/2/2016||Robert Petit||Insider||Sell||2,797||$8.32||$23,271.04||123,659|| |
|10/25/2016||Gregory T Mayes||Insider||Sell||19,162||$8.23||$157,703.26||103,087|| |
|8/9/2016||David Sidransky||Director||Sell||22,808||$15.01||$342,348.08||91,759|| |
|8/8/2016||Richard J Berman||Director||Sell||18,000||$15.21||$273,780.00||66,430|| |
|5/13/2016||Thomas J Mckearn||Director||Sell||4,100||$7.45||$30,545.00||82,120|| |
|5/2/2016||Daniel O'connor||CEO||Sell||8,237||$7.51||$61,859.87||316,661|| |
|5/2/2016||Robert Petit||Insider||Sell||2,785||$7.51||$20,915.35||128,025|| |
|3/31/2016||Robert Petit||Insider||Sell||3,325||$9.13||$30,357.25||131,164|| |
|3/16/2016||Thomas J Mckearn||Director||Sell||14,000||$8.25||$115,500.00||86,220|| |
|2/24/2016||Sara Bonstein||CFO||Sell||15,037||$5.58||$83,906.46||79,980|| |
|1/29/2016||Daniel O'connor||CEO||Sell||8,818||$6.88||$60,667.84||313,394|| |
|1/29/2016||Robert Petit||insider||Sell||3,099||$6.88||$21,321.12||130,557|| |
|10/26/2015||Gregory T Mayes||COO||Sell||19,231||$11.63||$223,656.53||119,821|| |
|10/20/2015||David J Mauro||Insider||Sell||24,586||$10.08||$247,826.88||165,932|| |
|8/24/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||300,000||$14.15||$4,245,000.00|| |
|4/30/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||500,000||$19.00||$9,500,000.00|| |
|2/18/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||684,762||$7.50||$5,135,715.00|| |
|5/9/2014||Richard J Berman||Director||Sell||14,530||$2.63||$38,213.90|| |
|3/31/2014||Daniel O'connor||CEO||Buy||3,333||$3.00||$9,999.00|| |
|10/24/2013||Daniel O'connor||CEO||Buy||13,500||$4.00||$54,000.00|| |
|10/24/2013||Mark J Rosenblum||CFO||Buy||12,000||$4.00||$48,000.00|| |
|10/24/2013||Robert Petit||Insider||Buy||12,800||$4.00||$51,200.00|| |
|10/24/2013||Roni Appel||Director||Buy||12,500||$4.00||$50,000.00|| |
Advaxis (NASDAQ ADXS) News Headlines
|Advaxis (ADXS) PT Lowered to $5.00|
www.americanbankingnews.com - March 18 at 12:26 PM
|Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT|
finance.yahoo.com - March 18 at 9:40 AM
|Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million|
www.americanbankingnews.com - March 17 at 8:38 AM
|FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)|
www.americanbankingnews.com - March 16 at 10:48 AM
|Q2 2018 Earnings Estimate for Advaxis, Inc. (ADXS) Issued By Jefferies Group|
www.americanbankingnews.com - March 15 at 7:54 AM
|Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Post Earnings of -$0.59 Per Share|
www.americanbankingnews.com - March 15 at 5:18 AM
|Advaxis (ADXS) Given a $6.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - March 14 at 10:50 PM
|Advaxis shares drop as cancer-drug study on hold after death - MarketWatch|
www.marketwatch.com - March 14 at 12:18 PM
|Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac ... - Business Wire (press release)|
www.businesswire.com - March 14 at 12:18 PM
|Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher|
www.benzinga.com - March 13 at 4:58 PM
|Advaxis' (ADXS) CEO Tony Lombardo on Q1 2018 Results - Earnings Call Transcript|
seekingalpha.com - March 13 at 10:54 AM
|Advaxis to Present at Upcoming March Conferences|
finance.yahoo.com - March 13 at 10:54 AM
|Advaxis shares drop as cancer-drug study on hold after death|
finance.yahoo.com - March 13 at 10:54 AM
|Advaxis (ADXS) Issues Quarterly Earnings Results|
www.americanbankingnews.com - March 13 at 10:20 AM
|Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies|
www.bizjournals.com - March 12 at 4:43 PM
|Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)|
finance.yahoo.com - March 12 at 4:43 PM
|Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?|
finance.yahoo.com - March 12 at 4:43 PM
|Advaxis reports 1Q loss|
finance.yahoo.com - March 12 at 4:43 PM
|Advaxis, Inc. (ADXS) Short Interest Update|
www.americanbankingnews.com - March 12 at 1:24 AM
|How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?|
finance.yahoo.com - March 9 at 4:54 PM
|Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018|
finance.yahoo.com - March 9 at 10:59 AM
|Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?|
finance.yahoo.com - March 8 at 10:32 AM
|Advaxis (ADXS) Set to Announce Earnings on Thursday|
www.americanbankingnews.com - March 1 at 1:30 AM
| Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million|
www.americanbankingnews.com - February 28 at 1:48 PM
|The No BS Plan: Week 2 Report - The Advaxis Apocalypse Is Nigh?|
seekingalpha.com - February 25 at 9:48 AM
|Advaxis (ADXS) Prices 10M Offering of Common Stock at $2/Share|
www.streetinsider.com - February 22 at 4:47 PM
|Advaxis Prices $20.0 Million Public Offering of Common Stock|
finance.yahoo.com - February 22 at 4:47 PM
|Advaxis looks to raise $20 million via share offering|
finance.yahoo.com - February 22 at 4:47 PM
|BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31|
www.reuters.com - February 22 at 9:12 AM
|Advaxis (ADXS) Plans Offering of Common Stock|
www.streetinsider.com - February 22 at 9:12 AM
|Advaxis Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - February 21 at 4:45 PM
|Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical Cancer in EU|
www.streetinsider.com - February 15 at 4:46 PM
|3 Things In Biotech You Should Learn Today: February 13, 2018|
seekingalpha.com - February 15 at 4:46 PM
|Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical ... - StreetInsider.com|
www.streetinsider.com - February 14 at 3:26 PM
|Advaxis Takes Its First Step Towards Regulatory Approval - Seeking Alpha|
seekingalpha.com - February 14 at 3:26 PM
|Advaxis (ADXS) Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for Treatment of ... - StreetInsider.com|
www.streetinsider.com - February 12 at 3:24 PM
|Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer|
finance.yahoo.com - February 12 at 3:24 PM
|$3.03 Million in Sales Expected for Advaxis, Inc. (ADXS) This Quarter|
www.americanbankingnews.com - February 11 at 4:30 AM
|-$0.58 EPS Expected for Advaxis, Inc. (ADXS) This Quarter|
www.americanbankingnews.com - February 9 at 2:34 PM
|Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies|
finance.yahoo.com - January 29 at 3:25 PM
|Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology|
finance.yahoo.com - January 25 at 3:25 PM
|Advaxis, Inc. (ADXS) Expected to Post Quarterly Sales of $3.03 Million|
www.americanbankingnews.com - January 25 at 4:22 AM
|TG Therapeutics (TGTX) and Advaxis (ADXS) Financial Contrast|
www.americanbankingnews.com - January 24 at 3:26 AM
|-$0.58 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter|
www.americanbankingnews.com - January 23 at 3:10 PM
|Zacks: Analysts Anticipate Advaxis, Inc. (ADXS) Will Announce Earnings of -$0.58 Per Share|
www.americanbankingnews.com - January 6 at 11:26 AM
|Sara Bonstein Sells 5,224 Shares of Advaxis, Inc. (ADXS) Stock|
www.americanbankingnews.com - January 3 at 7:54 PM
|Pre-Market Technical Scan on Biotech Equities -- Grifols, Advaxis, Nektar Therapeutics, and Spark Therapeutics|
www.prnewswire.com - January 3 at 10:50 AM
|Advaxis, Inc. (ADXS) to Post FY2018 Earnings of ($2.28) Per Share, Cantor Fitzgerald Forecasts|
www.americanbankingnews.com - December 30 at 10:02 PM
|Cantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price Target|
www.americanbankingnews.com - December 29 at 5:04 PM
|ETFs with exposure to Advaxis, Inc. : December 27, 2017|
finance.yahoo.com - December 27 at 12:48 PM
Advaxis (NASDAQ:ADXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement
Advaxis (NASDAQ ADXS) Stock Chart for Tuesday, March, 20, 2018